US stocks slipped on Friday afternoon, with carmakers and Chinese companies leading the decline, as the White House said ...

RBC Capital Markets increased its price target on Celestica (NYSE:CLS) shares from $115.00 to $140.00 while maintaining an Outperform rating. Currently trading at $131.66, near its 52-week high, ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $162.95, a high estimate of ...

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on Resmed (RMD – Research Report) on January 29 and set a price target of $238.00.

Imposing higher capital requirements on UBS as a systemically relevant bank will usher in higher costs for companies and ...

Britain’s biggest supermarket chain used data to gain an edge, but as rivals start to catch up, Michael Fahy looks at whether its growth prospects are worth buying into ...

RBC Capital analyst Nik Modi maintained a Hold rating on Energizer Holdings (ENR – Research Report) today and set a price target of $38.00. The ...

HSBC is preparing to wind down its M&A and equity capital markets businesses in Europe, the UK and the Americas as part of a ...

Key stocks in the Dow Jones Industrial Average (DJIA), including McDonald’s, JPMorgan, and Goldman Sachs. Analyze ratings, ...

On Friday, Exelixis Inc (EXEL) stock saw a decline, ending the day at $32.38 which represents a decrease of $-1.75 or -5.13% from the prior close of $34.13. The stock opened at $33.49 and touched a ...

UBS updated its outlook for U.S. midcap banks, revising earnings estimates and highlighting key performers in the sector. Analysts noted that since the start of bank earnings announcements last week, ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $36.43 which represents a slight increase of $0.23 or 0.64% from the prior close of $36.2. The stock opened at $36.44 and touched a low ...